Drug profile · INN
ibrexafungerp citrate
BREXAFEMME
ibrexafungerp citrate (BREXAFEMME) is a 1,3-beta-glucan synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — ibrexafungerp citrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ibrexafungerp citrate (BREXAFEMME) is a 1,3-beta-glucan synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
1,3-beta-glucan synthase inhibitor
Primary target: 1,3-beta-glucan synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ibrexafungerp citrate?
ibrexafungerp citrate (BREXAFEMME) is a 1,3-beta-glucan synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ibrexafungerp citrate?
BREXAFEMME is a marketed brand name for ibrexafungerp citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ibrexafungerp citrate?
ibrexafungerp citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.